samedan logo
 
 
spacer
home > white papers > Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections - IBT Bioservices
WHITE PAPERS
logo_IBT_Bioser0.jpg

IBT Bioservices

phone +1 877-411-2041
email services@ibtbioservices.com
web http://ibtbioservices.com/
email 21 Firstfield Road, Suite 100, Gaithersburg, MD 20878 USA

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

Introduction

Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.


spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Saneca Pharma strengthens senior team

Slovakia-based CDMO adds senior talent to its team to position the company for continued growth
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>


Industry Events

ManuPharma 2017

6-7 December 2017, Steigenberger Frankfurter Hof, Frankfurt

Europe's first peer-led pharma event for Heads of Tech Ops, Heads of Manufacturing Ops and Site Leads.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement